Phase III trial tests chemotherapy plus immunotherapy in MSI-H metastatic colorectal cancer

◆ TRIAL DATA

The phase III COMMIT trial randomly assigned first-line mismatch repair-deficient metastatic colorectal cancer patients in a three-arm study comparing mFOLFOX6/bevacizumab/atezolizumab versus atezolizumab monotherapy, testing whether adding chemotherapy to immunotherapy improves outcomes. (Journal of Clinical Oncology)